Lupus, formally known as systemic lupus erythematosus (SLE), is a complex autoimmune disease that affects various parts of the body, including the skin, joints, kidneys, heart, lungs, brain, and blood cells. It occurs when the immune system mistakenly attacks healthy tissues and organs, leading to inflammation, pain, and damage.
Lupus management often involves a multidisciplinary approach, where patients, healthcare professionals, researchers, and advocacy groups work together to improve the quality of life for those affected by the disease.
The mentioned industry players collaborate and contribute to advancing the understanding and treatment of lupus.
Established on October 1st 1847, the company has its headquarters in Erlangen, Germany. It is dedicated to providing a wide range of medical solutions, including diagnostic equipment, laboratory diagnostics, and healthcare IT solutions.
Siemens Healthineers offers diagnostic technologies and laboratory equipment used in the diagnosis and monitoring of lupus. For instance, it produces medical imaging machines (e.g., MRI or X-ray) that help visualize and assess the impact of lupus on organs and tissues. Additionally, it provides laboratory diagnostic equipment for running blood tests that can help in diagnosing and monitoring lupus, including tests for specific autoantibodies that are often elevated in lupus patients.
This company was established on September 23rd, 1948. Its headquarters are located in Otawara, Tochigi, Japan. It develops a comprehensive portfolio of medical imaging equipment and healthcare solutions.
With context to Lupus disease, it provides diagnostic imaging equipment like MRI and CT scanners, which can be valuable in diagnosing and monitoring the effects of lupus on organs and tissues. Additionally, their ultrasound systems can aid in evaluating specific aspects of the disease.
Wallace Calvin Abbot founded the company in 1888. Its headquarters are located in Chicago, Illinois, United States. It is a diversified company operating in various healthcare segments, including pharmaceuticals, diagnostics, medical devices, and nutrition.
Abbott Pharmaceuticals has been involved in the research and development of various pharmaceutical products used in the treatment of autoimmune diseases like lupus. These pharmaceutical products may include immunosuppressants, anti-inflammatory drugs, and biologics. It is known to have specific drugs in its portfolio or have been involved in research aimed at improving lupus treatments.
This biotech company was established by Phillip Allen Sharp, Walter Gilbert, Charles Weissmann, and Kenneth Murray in 1978. Its headquarters are located in Cambridge, Massachusetts, United States. t is a leader in the development and commercialization of therapies for neurological and autoimmune disorders.
Biogen’s involvement in the lupus treatment vertical is primarily through a medication called Benlysta (belimumab). Benlysta is a monoclonal antibody that is approved for the treatment of systemic lupus erythematosus (SLE), which is a type of lupus. It works by targeting a specific protein involved in the autoimmune response, thus helping to reduce disease activity.
This biotechnology company was set up in 2005 with its headquarters located in Dublin, Ireland. Horizon Therapeutics strives to improving the lives of patients with rare and rheumatic diseases by developing and delivering innovative therapies. It specializes in several therapeutic areas, with a particular focus on rare, autoimmune, and inflammatory diseases. These include conditions like gout, thyroid eye disease, and rheumatoid arthritis.
The company is known to play an active role in the lupus disease treatment vertical through its research and development efforts. Lupus, or systemic lupus erythematosus (SLE), is an autoimmune disease, and Horizon Therapeutics is involved in the development of therapies aimed at addressing lupus symptoms and underlying disease processes. This includes the development of new medications or therapies to improve the quality of life for lupus patients.
In the realm of lupus disease management, a collaborative effort is essential, with pharmaceutical companies driving drug development, healthcare professionals offering patient care, and patient advocacy groups providing resources and raising awareness. Researchers and academia contribute to scientific understanding, while government agencies ensure treatment safety and effectiveness. Technology and diagnostics companies deliver vital tools, and pharmacists assist with medication management. This multifaceted approach exemplifies the collective dedication to enhancing the lives of those grappling with lupus, addressing both the medical and patient-centric facets of the disease.